ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Docetaxel

Also written as “docetaxel”, “Taxotere” and “HB1801”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.

Drug pageDocetaxel: every studyMany companies study it; this page follows only the 142 they lead. All 1,164 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2006142 company-led studies, 15 open or runningNext primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only540 open or runningphase 4since Jan 18, 2006Nov 1, 1999none ahead
Hoffmann-La Rocheits history only220 open or runningphase 4since Aug 5, 2005Feb 12, 2004none ahead
CSPC Pharmaceutical Groupits history only1511 open or runningphase 3since Apr 20, 2023Mar 10, 2021Dec 16, 2026phase 3 · NCT06747338
Eli Lillyits history only81 open or runningphase 3since Nov 1, 2004Nov 1, 2004May 2027phase 2 · NCT05999994
Pfizerits history only70 open or runningphase 2since Jan 4, 2002Jan 4, 2002none ahead
GlaxoSmithKlineits history only60 open or runningphase 2since Jul 17, 2003Jul 17, 2003none ahead
Amgenits history only40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Merckits history only30 open or runningphase 2since Oct 4, 2007Oct 4, 2007none ahead
Novaceaits history only30 open or runningphase 3since Aug 9, 2002Aug 9, 2002none ahead
Novartisits history only20 open or runningphase 3since Jun 29, 2004Jun 29, 2004none ahead
Oshadi Drug Administration10 open or runningphase 2since May 7, 2014May 7, 2014none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Oshadi Drug Administration only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2014First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT02134990 · 20 enrolled · Israel

TargetBeta

“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

The one study Oshadi Drug Administration leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02134990Carcinoma, Non-Small-Cell Lung · Israel2UNKNOWNJan 201920

How it is read

Names in the registry

  • “Docetaxel”, 93 entries
  • “docetaxel”, 37 entries
  • “Taxotere”, 9 entries
  • “HB1801”, 8 entries
  • “Docetaxel for injection (Albumin-bound)”, 4 entries

Codes read as this program: CKD810.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.